Carnick & Kubik Group LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,948 shares of the medical research company’s stock after buying an additional 635 shares during the period. Carnick & Kubik Group LLC’s holdings in Thermo Fisher Scientific were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. Covington Capital Management boosted its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock worth $374,000 after purchasing an additional 20 shares in the last quarter. Investment Centers of America Inc. boosted its position in shares of Thermo Fisher Scientific by 1.6% during the 2nd quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock worth $230,000 after purchasing an additional 21 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock worth $1,090,000 after purchasing an additional 23 shares in the last quarter. Monetary Management Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.6% during the 2nd quarter. Monetary Management Group Inc. now owns 12,150 shares of the medical research company’s stock worth $2,120,000 after purchasing an additional 75 shares in the last quarter. Finally, Millie Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. Millie Capital Management LLC now owns 19,149 shares of the medical research company’s stock worth $3,341,000 after purchasing an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 86.11% of the company’s stock.

In related news, CFO Stephen Williamson sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $209.26, for a total value of $1,046,300.00. Following the completion of the transaction, the chief financial officer now owns 30,741 shares of the company’s stock, valued at approximately $6,432,861.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the transaction, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The disclosure for this sale can be found here. Insiders sold a total of 94,327 shares of company stock valued at $19,260,542 in the last three months. 0.49% of the stock is currently owned by corporate insiders.

Several brokerages have commented on TMO. ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Barclays boosted their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Leerink Swann restated an “outperform” rating and set a $239.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $220.50.

Thermo Fisher Scientific Inc. (NYSE TMO) opened at $203.50 on Wednesday. The stock has a market capitalization of $81,600.00, a price-to-earnings ratio of 36.34, a PEG ratio of 1.47 and a beta of 1.11. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. Thermo Fisher Scientific Inc. has a one year low of $151.74 and a one year high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.66 by $0.13. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The business’s revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.41 EPS. research analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s payout ratio is presently 10.71%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/02/14/carnick-kubik-group-llc-has-1-51-million-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.